BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Authors » James Etheridge

Articles by James Etheridge

Innate Pharma, Novo Nordisk Refocus Efforts on Inflammation

Feb. 6, 2008
By James Etheridge

Endotis Pharma Raises €25M to Move Small Glyco-Drugs

Jan. 30, 2008
By James Etheridge

Endotis Pharma Raises €25M to Move Small Glyco-Drugs

Jan. 30, 2008
By James Etheridge
No Abstract
Read More

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge
Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International)
Read More

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge
No Abstract BioWorld Today CorrespondentPARIS - Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline.
Read More

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

Jan. 23, 2008
By James Etheridge
Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International) 
Read More

France Suspends Cultivation of Monsanto's GM Corn

Jan. 16, 2008
By James Etheridge
PARIS - France has suspended the cultivation of genetically modified corn, which means Monsanto's MON 810 corn, the only GM corn containing a pesticide that was authorized for commercial cultivation in the country. (BioWorld International)
Read More

Genfit, Pierre Fabre Renew Metabolic Disorders Pact

Jan. 16, 2008
By James Etheridge

Genfit, Pierre Fabre Renew Metabolic Disorders Pact

Jan. 16, 2008
By James Etheridge
Previous 1 2 … 6 7 8 9 10 11 12 13 14 … 90 91 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 22, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 22, 2025.
  • Rubber duck dressed up as a doctor

    In 2025, science’s biggest story was political

    BioWorld
    In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
  • Abstract blue human heart with red cardio pulse line and red circle

    FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

    BioWorld
    Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...
  • Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

    BioWorld Science
    Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing